Skip Navigation LinksHome > March 21, 2006 - Volume 20 - Issue 5 > Effective therapy has altered the spectrum of cause-specific...
doi: 10.1097/01.aids.0000216375.99560.a2
Epidemiology and Social

Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion

CASCADE Collaboration

Free Access
Article Outline
Collapse Box

Author Information

*See Appendix

Received 20 October, 2005

Revised 6 January, 2006

Accepted 12 January, 2006

Requests for reprints to Dr K. Porter, MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK.

Correspondence to Colette Smit, Municipal Health Service, Amsterdam. Cluster of Infectious Diseases, HIV and STI Research, Nieuwe Achtergracht 100, 1018 WT Amsterdam, The Netherlands. E-mail:

Collapse Box


Introduction: Although HAART has led to a reduction in overall mortality among HIV-infected individuals, its impact on death from specific causes is unknown.

Methods: Twenty-two cohorts of HIV-infected individuals with known dates of seroconversion are pooled in the CASCADE collaboration. Causes of death (COD) were categorized into three AIDS-related and seven non-AIDS-related causes. The unknown causes were assigned a separate category. The cumulative incidence for each COD was calculated in the presence of the other competing COD, for the pre-HAART and HAART eras. A multivariate regression analyses for the cumulative rate of progression to the different COD was performed.

Results: A total of 1938 of 7680 HIV-seroconverters died. Pre-HAART, AIDS opportunistic infections (OI) was the most common COD, followed by unknown and HIV/AIDS-unspecified. In the HAART era, the cumulative incidence for all AIDS-related COD decreased, OI remaining the most important. Large reductions in death due to other infections and organ failure were seen. Cumulative death risk decreased in the HAART era for most causes. The effect of HAART was not the same for all risk groups. The cumulative risk of death from AIDS-related malignancies, OI and non-AIDS-related malignancies decreased significantly among homosexual men (MSM), whereas the risk of dying from (un)-intentional death increased significantly among injecting drug users (IDU). A non-significant increase in hepatitis/liver-related death was seen in MSM, IDU and haemophiliacs.

Conclusion: Overall and cause specific mortality decreased following the introduction of HAART. OI remain the most common COD in the HAART era, suggesting that AIDS-related events will continue to be important in the future. Future trends in COD should be monitored using standardized guidelines.

Back to Top | Article Outline


The life expectancy of HIV-infected individuals in the developed world has improved substantially since highly active antiretroviral therapy (HAART) became widely available from 1997 [1,2]. As HIV-infected persons live longer, they are increasingly more likely to die from non-HIV related causes [3,4], such as the consequences of co-infection with hepatitis viruses or aging, and increased exposure to HAART may place individuals at risk of death from therapy-related toxicities, including cardiovascular side-effects [5].

For example, the progression of liver disease associated with hepatitis C (HCV) infection is known to be accelerated in HIV-infected persons [6]. Due to the increasing survival of HIV-infected persons in the HAART era, mortality from HCV may take on a greater significance among HIV-infected drug users and haemophiliacs, in whom HCV infection is common. Chronic hepatitis B infection has also been shown to increase mortality among HIV-infected persons [7,8].

In the pre-HAART era, particularly in injecting drug users (IDU) and homosexual men, the risk of pre-AIDS mortality increased as the CD4 cell count decreased and HIV RNA level increased [9]. Among HIV-infected persons treated with HAART, the risk of death has also been shown to be associated with the CD4 cell count [10]. However, it is not clear whether these relationships are the same for all causes of death, or whether any relationship with the CD4 cell count or HIV RNA level may simply reflect a longer duration of infection in those with more advanced disease. The CASCADE cohort collaboration, which includes a large group of HIV-infected individuals with reliable estimated dates of seroconversion from all risk groups, provides a unique opportunity to describe in detail the incidence of death from different causes over the first 20 years following the start of the HIV epidemic, adjusting for the duration of HIV-infection.

We evaluated the impact of the introduction of HAART on cause-specific mortality and investigated the relationships between CD4 cell counts and HIV RNA levels and specific causes of death in this large collaboration.

Back to Top | Article Outline


Study population

Data from a collaboration of 22 HIV seroconverter cohort studies in Europe, Canada and Australia (CASCADE: Concerted Action on SeroConversion to AIDS and Death in Europe) were used for this analysis.

The CASCADE collaboration, which includes HIV-1 infected persons where a date of seroconversion can be estimated reliably, has been described in detail elsewhere [11]. Seroconverters were either enrolled into one of the constituent cohorts while HIV negative or else when already infected but with the ability to estimate HIV seroconversion through the availability of previously stored blood samples. The majority (85%) of seroconversion dates were calculated as the mid-point between the last negative and first positive HIV antibody tests; individuals in whom this period was greater than 3 years were excluded from current analysis (91% having an interval less than 2 years). Analyses were restricted to individuals from 19 cohorts that collected information on specific causes of death (COD). Children under 15 year of age at seroconversion were excluded.

Back to Top | Article Outline
Specific causes of death

Causes of death were grouped into 11 categories. These included three AIDS-related categories [AIDS-related malignancy, AIDS opportunistic infections (OI), AIDS/HIV-related unspecified] and seven non-AIDS-related causes [hepatitis/liver-related, other infections, organ failure, non-AIDS-related malignancy, (un)-intentional death (including accidents, suicide, overdose), cardiovascular disease (CVD)/diabetes mellitus and other (including epilepsy, fits, blood disorders)]. The final category consisted of the unknown COD, which could include AIDS-related as well as non-AIDS-related deaths. Most cohorts reported the primary COD for individuals who died, while some reported multiple COD. When more than one COD was given, the most likely underlying COD was scored independently by a panel of three physicians. Causes about which the physicians disagreed were reviewed by the panel until a final consensus was reached.

Back to Top | Article Outline

Follow-up was calculated from the estimated date of seroconversion until the earliest of: death, loss to follow-up, the cohort censoring date (each cohort had their own censoring date reflecting the processes and timelines in place for ascertaining events) or 31 December 2003. Those who were enrolled retrospectively into the constituent cohorts were included in the risk set from the date of cohort enrolment (i.e. a correction for left truncation was applied). We used calendar time as a proxy for the introduction and widespread use of HAART and defined two calendar periods, pre-1997 and 1997 onwards, to reflect the pre-HAART and HAART eras, respectively.

The cumulative incidences of all 11 categories of COD were calculated within a competing risks framework, for the pre-HAART and HAART eras separately [12]. Non-parametric estimates of cumulative transition probabilities from seroconversion to one of the competing COD were calculated using the multiple decrement model transition programme.

We also performed multivariate regression analyses for the rate of progression to the different COD [11,13] taking into account competing risks, allowing for late entry and adjusted for potential confounders. An administrative censoring time was created for each person who died of a COD that was not the COD of interest as this would be the date the person would have theoretically been alive at. Therefore, persons were censored at 1 January 1997 if they had died before that date from a COD that was not the COD of interest or at the cohort censoring date if they had died after it.

We evaluated the effect of calendar time within each risk group, as well as the interaction between risk group and calendar time for each COD. Hazards ratios were only calculated for COD with more than five deaths. To reduce the chance of a type 1 error as a result of multiple testing, we also calculated 99% confidence intervals (CI). All models were adjusted for sex, age at seroconversion, and presentation during acute HIV infection (defined when the interval between the last HIV-negative and first HIV positive test was less than 1 month [14]).

To evaluate the impact of HAART on the relationships between the CD4 cell count, HIV RNA level and each specific COD, the cause-specific hazard ratios (CHR) were estimated using a Cox proportional hazards model for progression from HIV seroconversion to each cause. In this analysis these markers were evaluated as continuous variables (after square-root and logarithmic transformation, respectively) and were treated as time-dependent covariates. If the interval between two consecutive marker measurements or between the last measurement and either death or end of follow-up exceeded 18 months, individuals were temporarily removed from the risk set from the 18-month point until the date of their next available measurement.

Finally, a sensitivity analysis was conducted by excluding data from all cohorts in which more than 25% of the COD were unknown.

Back to Top | Article Outline


The median age of the 7680 seroconverters included in the analyses was 29 years [interquartile range (IQR), 24–35] and 81% were male. Sex between men was the most frequent exposure category (49%) followed by IDU (25%), sex between men and women (15%) and haemophilia (3%). A total of 1938 of the 7680 seroconverters died during follow up (26%); a specific COD was available for 1437 of these deaths (74%, Table 1). Of these 1938 deaths, 248 patients had more than one COD and 1424 of the deaths (72%) occurred in individuals who had been diagnosed with AIDS.

Table 1
Table 1
Image Tools
Back to Top | Article Outline
Cumulative incidences

The cumulative incidence of all cause mortality was 0.10 at 5 years and 0.44 at 10 years following seroconversion in the pre-HAART era. The cumulative incidences of all cause mortality were 0.05 at 5 years and 0.15 at 10 years in the HAART era (Fig. 1). For those who became infected after the introduction of HAART, and were, therefore, potentially able to fully benefit from HAART, the 5-year cumulative incidence of all cause mortality was 0.02.

Fig. 1
Fig. 1
Image Tools

Cumulative incidences for each specific COD are shown in Fig. 2a and b. In the pre-HAART era, AIDS OI was the most common cause, followed by unknown causes, HIV/AIDS not further specified and other infections. A small proportion (3% at 15 years following seroconversion, 95% CI, 2–4) died from hepatitis/liver-related causes (Fig. 2a).

Fig. 2
Fig. 2
Image Tools

In contrast, in the HAART era (Fig. 2b), unknown deaths was the most common category. All AIDS-related COD decreased by at least 50% in the HAART era. At 15 years after seroconversion, the cumulative probability of dying from AIDS OI decreased from 20% (95% CI, 17–23) in the pre-HAART era to 5% in the HAART era (95% CI, 4–6). However, AIDS OI remained the most important known COD. HIV/AIDS not further specified became a less important COD in the HAART era. Although the percentage of persons dying from AIDS-related malignancies is small, it also halved in the HAART era, in comparison with the pre-HAART era. Although the probability of dying from hepatitis or liver-related causes did not change in the era after HAART was introduced, the probability of dying from other infections decreased from 8% at 15 years following seroconversion (95% CI, 6–9) in the pre-HAART era to 3% (95% CI, 3–4) in the HAART era. Death from organ failure also showed a large reduction, from 1% in the pre-HAART era to 0.4% in the HAART era.

Back to Top | Article Outline
Cumulative risks

We compared the risk of dying from each specific COD in the pre-HAART era with the risk of dying from that COD in the HAART era. The effect of calendar time was not the same for each risk group. Therefore, the relative hazards for each risk group are shown separately in Fig. 3. Within each risk group the risk of dying in the HAART era is compared with the risk of dying from the same cause in the pre-HAART era (left column of Fig. 3). We also compared the risk of dying among IDUs, heterosexuals and haemophiliacs to that among men who have sex with men (MSM), separately for the pre-HAART and HAART eras (middle and right column).

Fig. 3
Fig. 3
Image Tools
Back to Top | Article Outline
Changes in risks of dying in the HAART era within each risk group

Among MSM, there was a reduction in the cumulative risk of dying from most COD in the HAART era in comparison with the pre-HAART era. Large cumulative risk reductions were seen for AIDS-related malignancies, AIDS OI and the unknown categories. All reductions in cumulative risks were significant at the 5% level, with the exception of organ failure. Although not significant, the cumulative risk of dying from organ failure strongly decreased. However, a small non-significant increase in the cumulative risk of dying from hepatitis/liver-related causes and CVD/diabetes mellitus was seen.

Among IDU, a significant reduction was observed in the cumulative risk of death from AIDS OI and a large significant reduction was seen in the cumulative risk of death from non-AIDS-related malignancy. The cumulative risks of dying from AIDS-related malignancies, other infections and organ failure were all reduced, but these reductions were not significant. For the organ failure category, the cumulative risk strongly reduced. However, the cumulative risk of dying from (un)-intentional death increased significantly, whereas a non-significant increase in the cumulative risk of dying from hepatitis/liver-related causes was seen.

In heterosexuals, strong reductions in the cumulative risk of dying from AIDS-related malignancies, AIDS OI, other infections, hepatitis/liver-related death and (un) intentional death were seen, although the effect was not significant for AIDS-related malignancies and hepatitis/liver-related causes. A non-significant increase was seen for the cumulative risks of dying from non-AIDS-related malignancies and CVD/diabetes mellitus.

Finally, among haemophiliacs, no significant reductions or increases in the risks of dying were seen, although there was a large increase in the cumulative risk of dying from hepatitis/liver-related causes, organ failure and non-AIDS-related malignancies.

Back to Top | Article Outline
Comparison of the risk of death between risk groups

In the pre-HAART era, we observed a significantly higher cumulative risk of death among IDUs in comparison with MSM, from AIDS OI, hepatitis or liver-related deaths, other infections and (un)-intentional death. A significantly cumulative lower risk was observed for AIDS and non-AIDS-related malignancies, unspecified HIV/AIDS-related deaths and unknown in IDUs. In the HAART era, IDU had a higher cumulative risk of death in comparison with MSM for all COD, except non-AIDS-related malignancies. The cumulative risks of death from AIDS OI, hepatitis/liver-related causes, (un)-intentional causes and unknown COD were significantly higher. Pre-HAART, heterosexuals had a significantly higher cumulative risk of death from other infections in comparison with MSM, whereas no significant differences were seen in the cumulative risks of death from other specific COD. In the HAART era, no significant differences were found in the cumulative risks of each specific COD between heterosexuals and MSM.

In the pre-HAART era, haemophiliacs had a significantly lower cumulative risk of death from AIDS-related malignancies, AIDS OI, other infections and unknown COD in comparison with MSM. The cumulative risk of dying from unspecified HIV/AIDS-related causes, hepatitis/liver-related causes and CVD/diabetes mellitus increased. After HAART became available, the cumulative risk of death from hepatitis/liver-related causes remained significantly higher.

Back to Top | Article Outline
Association between laboratory markers and specific causes of death

All COD showed a significant relationship with lower CD4 cell counts, except (un)-intentional death in the pre-HAART era (Table 2).

Table 2
Table 2
Image Tools

For almost all COD, the relationship with the CD4 cell count did not differ significantly in the HAART era, compared to the pre-HAART era. However, the relationships between the CD4 cell count and the risk of dying from unknown COD was significantly weaker in the HAART era.

Fewer HIV RNA data were available in the pre-HAART era, due to the lack of availability of these tests at that time. None of the relationships between the COD and higher HIV RNA levels differed between the pre-HAART and HAART eras, with the exception of the relationship between HIV RNA levels and unknown COD, which was weaker in the era of HAART (Table 2). The relationship between organ failure and HIV RNA levels became stronger in the era of HAART (P = 0.05).

Back to Top | Article Outline


This study, conducted among a large group of HIV-infected individuals with well-estimated dates of seroconversion followed in the pre-HAART and HAART eras, demonstrates clearly that the probability of dying from most causes of death decreased substantially after HAART became widely available. Nevertheless, although the cumulative incidence of death from all AIDS-related causes decreased in the era of HAART, AIDS OI still remained the most common COD.

Although individuals in the pre-HAART era may have been infected with HIV for longer periods of time than those in the HAART era, it is unlikely that our findings can be explained by differences in duration of infection between those followed in the in the two time periods because we were able to adjust our analyses for the time since seroconversion.

However, the population in which mortality can be estimated in the first years following the introduction of HAART does inevitable include many individuals infected in the pre-HAART era, some of whom would have had limited opportunity to benefit from HAART, for example due to very low CD4 cell counts at HAART initiation [15] or prior use of sub-optimal treatments [16]. For those who did become infected in the HAART era, however, who had the opportunity to fully benefit from HAART, we found that mortality was even lower than the wider population at risk in the HAART era, suggesting that further reductions in mortality in HIV-infected persons may emerge over time [15].

A reduction in AIDS-related mortality at the population level following the widespread use of HAART has been shown in earlier studies [17–21]. However, our study is the first to show a general reduction in the risk of dying from specific causes in seroconverters in the era of HAART. Interestingly, the benefits of HAART appear to be less strong in IDU across the specific causes. Furthermore, the cumulative risk of dying from (un) intentional causes significantly increased among IDU in the HAART era. One reason could be temporal changes in other risk factors (e.g. injecting behaviour). However, as fewer IDU are now dying from the other specific causes investigated in our study, more IDU remain at risk of dying from (un) intentional causes, therefore in the HAART era more IDU will die from this cause leading to an increase in the cumulative risk. In line with a study from the pre-HAART era these deaths are not associated with having lower CD4 cell counts [22]. All other COD, including non-AIDS-related COD, were associated with lower CD4 cell counts, with virtually no differences in the association with CD4 cell count between the HAART and pre-HAART eras. Hence all COD, other than (un)intentional deaths, appeared to be related in some way to the underlying immunodeficiency caused by HIV infection regardless of their putative association with AIDS itself. Similarly, the relationship between HIV RNA levels and the risk of all COD remained virtually unchanged in the HAART era, although this relationship did become slightly weaker for unknown COD, perhaps suggesting that many unknown causes in the pre-HAART era were, in fact, HIV-related.

Other studies have shown that hepatitis/liver-related deaths and malignancies are now the most common non-AIDS-related COD among HIV-infected individuals [10]. Among HIV-infected individuals who died, the proportion of deaths accounted for by these COD and CVD have increased since 1996 [23]. Although we found that the risk of dying from CVD increased, (un)-intentional death, other infections and hepatitis/liver-related deaths were the most common non-AIDS-related COD in the HAART era in our study. We believe this highlights one of the limitations of conducting studies based only on persons who have died, since these cannot account for the substantially larger number of persons surviving in the HAART era. Our study shows a trend towards a higher probability of dying from hepatitis/liver-related causes in the HAART era among most risk groups, in line with other studies [24,25], and most likely because large numbers of patients survive to experience this competing COD. However, this finding is not supported by Qurishi et al. [26], most likely due to survivorship bias not accounted for in their analyses [27].

Since HAART became generally available, several studies have demonstrated reductions in the incidence of AIDS-related malignancies among HIV-infected persons [28,29] and we found parallel reductions in the incidence of death from AIDS-related malignancies. However, we observed a small non-significant increase in the risk of death from non-AIDS-related malignancies in the HAART era among heterosexuals in our study. Furthermore, although cancer rates among those with HIV have not markedly increased in the HAART era [30], HIV-infected individuals do have an increased risk of non-AIDS-related cancers in comparison with the general population [31].

One limitation of our study is the lack of uniform classification of COD within cohorts that participate in the CASCADE collaboration with each cohort using their own classification. Differences in COD distribution were observed when comparing the cohorts that reported one COD with the cohorts that reported multiple causes. In particular, cohorts with one COD were more likely to report unspecified AIDS/HIV-related causes than cohorts with multiple COD, suggesting that deaths were allocated a COD according to a hierarchy. This difference in process might cause some bias and it is possible that the proportion of deaths due to AIDS/HIV-related causes may be underestimated. A recent study has shown that the lack in precise information about the COD might result in misinterpretation of results [32], so a standardized classification of COD among HIV-infected persons is needed The recent CoDe project provides such a uniform system for collecting and classifying the COD ( and this may help to further improve the quality of reporting in the future and allow monitoring of trends in COD. Another limitation of our study is the relatively large proportion of deaths from unknown causes. However, a sensitivity analysis restricted to cohorts in which less than 25% of the deaths were from unknown causes showed no major differences in findings, except that in the era of HAART, the cumulative incidence of hepatitis/liver-related deaths became somewhat higher. This suggests that hepatitis/liver-related deaths might become even more important as classification of deaths improves in the future.

In conclusion, both overall mortality as well as cause-specific mortality has substantially decreased following the introduction of HAART. However, AIDS OI remain the most common COD in the era of HAART, suggesting that AIDS-related events will continue to be an important cause of death in the future. Since the time after HAART became available is limited and the majority of HIV-infected individuals in our study became infected in the pre-HAART era, it might be too early to observe an increase in non-AIDS-related death due to therapy-related toxicities. Therefore monitoring mortality trends among HIV-infected individuals using standardized international guidelines for the coding of deaths among HIV-infected persons will be essential for the future. Furthermore, the development of prevention measures and treatment guidelines for non-AIDS-related conditions aimed specifically at HIV-infected individuals is warranted.

Back to Top | Article Outline


The authors wish to thank the panel of physicians: Court Pedersen, Karen Lindenburg, Cees Das.

Back to Top | Article Outline


1. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267–1274.

2. Palella FJ, Delaneny KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853–860.

3. Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995–1999. Clin Infect Dis 2001; 32:1487–1493.

4. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663–1671.

5. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, et al. Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179–1193.

6. Telfer P, Sabin C, Devereux H, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87:555–561.

7. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593–601.

8. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921–1926.

9. Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS 2000; 14:1829–1837.

10. Lewden C, Raffi F, Cuzin L, Cailleton V, Vilde JL, Chene G, et al. Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiproteases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study. J Infect Dis 2002; 186:710–714.

11. Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker SA, et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002; 31:951–958.

12. Tai BC, Machin D, White I, Gebski V. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Stat Med 2001; 20:661–684.

13. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 446:496–509.

14. CASCADE. The relationships between the HIV test interval, demographic factors and HIV disease progression. Epidemiol Infect 2001; 127:91–100.

15. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22–29.

16. Yamashita TE, Phair JP, Munoz A, Margolick JB, Detels R, O'Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735–746.

17. Smit C, Geskus R, Uitenbroek D, Mulder D, Van den Hoek A, Coutinho RA, et al. Declining AIDS mortality in Amsterdam: contributions of declining HIV incidence and effective therapy. Epidemiology 2004; 15:536–542.

18. Chiasson MA, Berenson L, Li W, Schwartz S, Singh T, Forlenza S, et al. Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr 1999; 21:59–64.

19. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349:1294.

20. Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R, et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004; 18:1835–1843.

21. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497–1503.

22. Prins M, Hernandez A, I, Brettle RP, Robertson JR, Broers B, Carre N, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997; 11:1747–1756.

23. Selik RM, Byers RHJ, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987–1999. J Acquir Immune Defic Syndr 2002; 29:378–387.

24. Serraino D, Boschini A, Carrieri P, Pradier C, Dorrucci M, Dal Maso L, et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 2000; 14:553–559.

25. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492–497.

26. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708–1713.

27. Sabin CA, Walker AS, Dunn D. HIV/HCV coinfection, HAART, and liver-related mortality. Lancet 2004; 364:757–758.

28. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823–1830.

29. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.[see comment]. J Natl Cancer Inst 2005; 97:425–432.

30. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16:1155–1161.

31. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15:1–4.

32. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, et al. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 2004; 18:2333–2337.

Back to Top | Article Outline
CASCADE collaboration

Analysis and writing committee: Colette Smit, Ronald Geskus, Sarah Walker, Caroline Sabin, Roel Coutinho, Kholoud Porter, Maria Prins.

Steering committee: Valerie Beral, Roel Coutinho, Janet Darbyshire (project leader), Julia Del Amo, Noël Gill (chairman), Christine Lee, Laurence Meyer, Giovanni Rezza.

Co-ordinating centre: Kholoud Porter (scientific co-ordinator), Abdel Babiker, A. Sarah Walker, Janet Darbyshire, Krishnan Bhaskaran.

Collaborators: Aquitaine cohort, France: Francois Dabis, Rodolphe Thiébaut, Geneviève Chêne, Sylvie Lawson-Ayayi; SEROCO cohort, France: Laurence Meyer, Faroudy Boufassa; German cohort, Germany: Osamah Hamouda, Gabriele Poggensee; Italian Seroconversion Study, Italy: Benedetta Longo, Patrizio Pezzotti, Giovanni Rezza; Greek Haemophilia cohort, Greece: Giota Touloumi, Angelos Hatzakis, Anastasia Karafoulidou, Olga Katsarou; Edinburgh Hospital cohort, United Kingdom: Ray Brettle; Madrid cohort, Spain: Julia Del Amo, Jorge del Romero; Amsterdam Cohort Studies among homosexual men and drug users, the Netherlands: Liselotte van Asten, Akke van der Bij, Ronald Geskus, Maria Prins, Roel Coutinho; Copenhagen cohort, Denmark: Court Pedersen; Valencia IDU cohort, Spain: Ildefonso Hernández Aguado, Santiago Pérez-Hoyos; Oslo and Ulleval Hospital cohorts, Norway: Anne Eskild, Johan N Bruun, Mette Sannes; Royal Free haemophilia cohort, United Kingdom: Caroline Sabin, Christine Lee; UK Register of HIV Seroconverters, United Kingdom: Anne M Johnson, Andrew N Phillips, Abdel Babiker, Janet H Darbyshire, Noël Gill, Kholoud Porter; Swiss HIV cohort, Switzerland: Patrick Francioli, Philippe Vanhems, Matthias Egger, Martin Rickenbach; Sydney AIDS Prospective Study, Australia: David Cooper, John Kaldor; Sydney Primary HIV Infection cohort, Australia: David Cooper, John Kaldor, Tim Ramacciotti, Don Smith; Badalona IDU hospital cohort, Spain: Roberto Muga, Jordi Tor; Lyon Primary Infection cohort, France: Philippe Vanhems; South Alberta clinic, Canada: John Gill; Barcelona IDU cohort, Spain: Joan Cayla, Patricia Garcia de Olalla.

Cited By:

This article has been cited 88 time(s).

Critical Reviews in Immunology
Dimethyl Fumarate Modulation of Immune and Antioxidant Responses: Application to HIV Therapy
Gill, AJ; Kolson, DL
Critical Reviews in Immunology, 33(4): 307-359.

Bmc Infectious Diseases
All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010
Hernando, V; Alejos, B; Monge, S; Berenguer, J; Anta, L; Vinuesa, D; Palacios, R; Muga, R; Moreno, S; Jarrin, I
Bmc Infectious Diseases, 13(): -.
ARTN 382
Nicotine & Tobacco Research
Safety of Varenicline Among Smokers Enrolled in the Lung HIV Study
Ferketich, AK; Diaz, P; Browning, KK; Lu, B; Koletar, SL; Reynolds, NR; Wewers, ME
Nicotine & Tobacco Research, 15(1): 247-254.
HIV Medicine
Ten-year mortality trends among persons diagnosed with HIV infection in England and Wales in the era of antiretroviral therapy: AIDS remains a silent killer
Simmons, RD; Ciancio, BC; Kall, MM; Rice, BD; Delpech, VC
HIV Medicine, 14(): 596-604.
Plos One
Changing Mortality Profile among HIV-Infected Patients in Rio de Janeiro, Brazil: Shifting from AIDS to Non-AIDS Related Conditions in the HAART Era
Grinsztejn, B; Luz, PM; Pacheco, AG; Santos, DVG; Velasque, L; Moreira, RI; Guimaraes, MRC; Nunes, EOP; Lemos, AS; Ribeiro, SR; Campos, DP; Vitoria, MAA; Veloso, VG
Plos One, 8(4): -.
ARTN e59768
Revista Da Sociedade Brasileira De Medicina Tropical
Malignancies in HIV/AIDS patients attending an outpatient clinic in Vitoria, State of Espirito Santo, Brazil
Neto, LFDP; Milanez, MD; Golub, JE; Miranda, AEB
Revista Da Sociedade Brasileira De Medicina Tropical, 45(6): 687-690.

Plos One
A Comparison of HAART Outcomes between the US Military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS)
Guest, JL; Weintrob, AC; Rimland, D; Rentsch, C; Bradley, WP; Agan, BK; Marconi, VC
Plos One, 8(5): -.
ARTN e62273
Journal of Korean Medical Science
Trends of Mortality and Cause of Death among HIV-Infected Patients in Korea, 1990-2011
Lee, SH; Kim, KH; Lee, SG; Chen, DH; Jung, DS; Moon, CS; Park, JY; Chung, JS; Kwak, IS; Cho, GJ
Journal of Korean Medical Science, 28(1): 67-73.
Annals Academy of Medicine Singapore
Causes of Death and Factors Associated with Early Death Among Human Immunodeficiency Virus (HIV)-Infected Persons in Singapore: Pre-Highly Active Antiretroviral Therapy (HAART) and Peri-HAART
Chow, A; Tey, J; Win, MK; Leo, YS
Annals Academy of Medicine Singapore, 41(): 563-570.

Annals Academy of Medicine Singapore
Causes of Death in Hospitalised Human Immunodeficiency Virus (HIV)-infected Patients at a National Referral Centre in Singapore: A Retrospective Review from 2008 to 2010
Wong, CS; Lo, FA; Cavailler, P; Ng, OT; Lee, CC; Leo, YS; Chua, AC
Annals Academy of Medicine Singapore, 41(): 571-576.

Seminars in Nuclear Medicine
FDG-PET Imaging in HIV Infection and Tuberculosis
Sathekge, M; Maes, A; Van de Wiele, C
Seminars in Nuclear Medicine, 43(5): 349-366.
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
de Vos, AS; van der Helm, JJ; Matser, A; Prins, M; Kretzschmar, MEE
Addiction, 108(6): 1070-1081.
Human Reproduction Update
Reproductive assistance in HIV serodiscordant couples
Savasi, V; Mandia, L; Laoreti, A; Cetin, I
Human Reproduction Update, 19(2): 136-150.
Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997
van der Helm, J; Geskus, R; Sabin, C; Meyer, L; del Amo, J; Chene, G; Dorrucci, M; Muga, R; Porter, K; Prins, M
Gastroenterology, 144(4): 751-+.
HIV Medicine
Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005
Yang, CH; Huang, YF; Hsiao, CF; Yeh, YL; Liou, HR; Hung, CC; Yang, SY
HIV Medicine, 9(7): 535-543.
British Medical Journal
HIV infection in older people
Gebo, KA
British Medical Journal, 338(): -.
ARTN b1460
Current HIV Research
Increase in the non-HIV-related deaths among aids cases in the HAART era
Novoa, AM; de Olalla, PG; Clos, R; Orcau, A; Rodriguez-Sanz, M; Cayla, JA
Current HIV Research, 6(1): 77-81.

HIV Clinical Trials
Determination of the underlying cause of death in three multicenter international HIV clinical trials
Lifson, AR; Belloso, WH; Carey, C; Davey, RT; Duprez, D; El-Sadr, WM; Gatell, JM; Gey, DC; Hoy, JF; Krum, EA; Nelson, R; Nixon, DE; Paton, N; Pedersen, C; Perez, G; Price, RW; Prineas, RJ; Rhame, FS; Sampson, J; Worley, J
HIV Clinical Trials, 9(3): 177-185.
Clinical Infectious Diseases
Causes of Death in HIV-1-Infected Patients Treated with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 HIV Cohort Studies
Gill, J; May, M; Lewden, C; Saag, M; Mugavero, M; Reiss, P; Ledergerber, B; Mocroft, A; Harris, R; Fux, CA; Justice, A; Costagliola, D; Casabona, J; Hogg, RS; Khaykin, P; Lampe, F; Vehreschild, J; Sterne, JAC; Egger, M; Brodt, HR; Casabona, J; Chene, G; Costagliola, D; Dabis, F; Monforte, AD; de Wolf, F; Fatkenheuer, G; Gill, J; Guest, J; Hogg, RS; Justice, A; Kirk, O; Kitahata, M; Lampe, F; Ledergerber, B; Reiss, P; Sterling, T
Clinical Infectious Diseases, 50(): 1387-1396.
Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART
Chiappini, E; Galli, L; Tovo, PA; Gabiano, C; Lisi, C; Gattinara, GC; Esposito, S; Vigano, A; Giaquinto, C; Rosso, R; Guarino, A; de Martino, M
AIDS, 21(): 1607-1615.

Nature Medicine
Getting personal about treating HIV
Neaton, JD; Lane, HC
Nature Medicine, 14(4): 369-370.
Gastrointestinal complications of HIV infection: changing priorities in the HAART era
Wilcox, CM; Saag, MS
Gut, 57(6): 861-870.
International Journal of Tuberculosis and Lung Disease
Tuberculosis as primary cause of death among ADS cases in Rio de Janeiro, Brazil
Saraceni, V; King, BS; Cavalcante, SC; Golub, JE; Lauria, LM; Moulton, LH; Chaisson, RE; Durovni, B
International Journal of Tuberculosis and Lung Disease, 12(7): 769-772.

Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005
Buchacz, K; Baker, RK; Moorman, AC; Richardson, JT; Wood, KC; Holmberg, SD; Brooks, JT
AIDS, 22(): 1345-1354.

Jama-Journal of the American Medical Association
Antiretroviral treatment of adult HIV infection - 2008 recommendations of the International AIDS Society USA panel
Hammer, SM; Eron, JJ; Reiss, P; Schooley, RT; Thompson, MA; Walmsley, S; Cahn, P; Fischl, MA; Gatell, JM; Hirsch, MS; Jacobsen, DM; Montaner, JSG; Richman, DD; Yeni, PG; Volberding, PA
Jama-Journal of the American Medical Association, 300(5): 555-570.

Medicina Clinica
Effect of highly active antiretroviral treatment in HIV infection: role of epidemiological studies
Perez-Hoyos, S
Medicina Clinica, 127(5): 175-176.

Clinical Infectious Diseases
Improving survival among HIV-infected injection drug users: How should we define success?
Kirk, GD; Vlahov, D
Clinical Infectious Diseases, 45(3): 377-380.
International Journal of Drug Policy
HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management
Lazarus, JV; Shete, PB; Eramova, I; Merkinaite, S; Matic, S
International Journal of Drug Policy, 18(5): 426-432.
Current HIV Research
The Changing Face of HIV/AIDS in Treated Patients
Llibre, JM; Falco, V; Tural, C; Negredo, E; Pineda, JA; Munoz, J; Ortega, E; Videla, S; Sirera, G; Martinez, E; Miralles, C; Iribarren, J; Galindo, MJ; Domingo, P; d'Arminio-Monforte, A; Miro, JM; Clotet, B
Current HIV Research, 7(4): 365-377.

Current HIV Research
Mortality and morbidity of HIV infected patients receiving HAART: A cohort study
Panos, G; Samonis, G; Alexiou, VG; Kavarnou, GA; Charatsis, G; Falagas, ME
Current HIV Research, 6(3): 257-260.

Clinical Infectious Diseases
HIV-Associated Opportunistic Infections-Going, Going, But Not Gone: The Continued Need for Prevention and Treatment Guidelines
Brooks, JT; Kaplan, JE; Holmes, KK; Benson, C; Pau, A; Masur, H
Clinical Infectious Diseases, 48(5): 609-611.
Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Na < ve to Antiretroviral Therapy
Antinori, A; Ammassari, A; Torti, C; Marconi, P; Andreoni, M; Angarano, G; Bonora, S; Castagna, A; Cauda, R; Clerici, M; Monforte, AD; De Luca, A; Di Perri, G; Galli, M; Girardi, E; Gori, A; Lazzarin, A; Lo Caputo, S; Mazzotta, F; Montella, F; Mussini, C; Perno, CF; Puoti, M; Rizzardini, G; Rusconi, S; Vullo, V; Carosi, G
Infection, 37(3): 270-282.
International Journal of Epidemiology
Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalite 2000 & 2005' Surveys (ANRS EN19)
Hessamfar-Bonarek, M; Morlat, P; Salmon, D; Cacoub, P; May, T; Bonnet, F; Rosenthal, E; Costagliola, D; Lewden, C; Chene, G
International Journal of Epidemiology, 39(1): 135-146.
Enfermedades Infecciosas Y Microbiologia Clinica
Assessment and management of kidney disease in the HIV-1-infected patient. A practical review
Domingo, P; Knobel, H; Gutierrez, F; Barril, G; Fulladosa, X
Enfermedades Infecciosas Y Microbiologia Clinica, 28(3): 185-198.
Cause of death and presence of respiratory disease at autopsy in an HIV-1 seroconversion cohort of southern African gold miners
Murray, J; Sonnenberg, P; Nelson, G; Rester, A; Shearer, S; Glynn, JR
AIDS, 21(): S97-S104.

The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users
Ferreros, I; Lumbreras, B; Hurtado, I; Perez-Hoyos, S; Hernandez-Aguado, I
Addiction, 103(4): 651-659.

American Journal of Epidemiology
Copy-Years Viremia as a Measure of Cumulative Human Immunodeficiency Virus Viral Burden
Cole, SR; Napravnik, S; Mugavero, MJ; Lau, B; Eron, JJ; Saag, MS
American Journal of Epidemiology, 171(2): 198-205.
HIV Medicine
Association between HIV infection and attenuated diurnal blood pressure rhythm in untreated hypertensive individuals
Baekken, M; Os, I; Stenehjem, A; Sandvik, L; Oektedalen, O
HIV Medicine, 10(1): 44-52.
New England Journal of Medicine
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, MM; Gange, SJ; Abraham, AG; Merriman, B; Saag, MS; Justice, AC; Hogg, RS; Deeks, SG; Eron, JJ; Brooks, JT; Rourke, SB; Gill, MJ; Bosch, RJ; Martin, JN; Klein, MB; Jacobson, LP; Rodriguez, B; Sterling, TR; Kirk, GD; Napravnik, S; Rachlis, AR; Calzavara, LM; Horberg, MA; Silverberg, MJ; Gebo, KA; Goedert, JJ; Benson, CA; Collier, AC; Van Rompaey, SE; Crane, HM; McKaig, RG; Lau, B; Freeman, AM; Moore, RD
New England Journal of Medicine, 360(): 1815-1826.
Journal of Viral Hepatitis
Comparison of deaths related to hepatitis C and AIDS in Scotland
Palmateer, NE; Hutchinson, SJ; McLeod, A; Codere, G; Goldberg, DJ
Journal of Viral Hepatitis, 14(): 870-874.
Social Dynamics-A Journal of the Centre for African Studies University of Cape Town
The quest for healing in South Africa's age of AIDS
Nattrass, N
Social Dynamics-A Journal of the Centre for African Studies University of Cape Town, 31(2): 1-23.

Annals of Internal Medicine
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy - a randomized trial
El-Sadr, WM; Grund, B; Neuhaus, J; Babiker, A; Cohen, CJ; Darbyshire, J; Emery, S; Lundgren, JD; Phillips, A; Neaton, JD
Annals of Internal Medicine, 149(5): 289-W62.

Journal of Clinical Investigation
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment
Levy, Y; Lacabaratz, C; Weiss, L; Viard, JP; Goujard, C; Lelievre, JD; Boue, F; Molina, JM; Rouzioux, C; Avettand-Fenoel, V; Croughs, T; Beq, S; Thiebaut, R; Chene, G; Morre, M; Delfraissy, JF
Journal of Clinical Investigation, 119(4): 997-1007.
Plos One
Increase in Non-AIDS Related Conditions as Causes of Death among HIV-Infected Individuals in the HAART Era in Brazil
Pacheco, AG; Tuboi, SH; Faulhaber, JC; Harrison, LH; Schechter, M
Plos One, 3(1): -.
ARTN e1531
Journal of Palliative Medicine
Prognosis in HIV and AIDS #213
Oppenheim, S
Journal of Palliative Medicine, 12(9): 833-835.
Enfermedades Infecciosas Y Microbiologia Clinica
Analytical methods in cohort studies of patients with HIV infection
Jarrin, I; Geskus, R; Perez-Hoyos, S; del Amo, J
Enfermedades Infecciosas Y Microbiologia Clinica, 28(5): 298-303.
HIV Medicine
Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy
Grabar, S; Lanoy, E; Allavena, C; Mary-Krause, M; Bentata, M; Fischer, P; Mahamat, A; Rabaud, C; Costagliola, D
HIV Medicine, 9(4): 246-256.
Brazilian Journal of Infectious Diseases
Recurring Candida albicans esophagitis in a HIV-infected patient undergoing long-term antiretroviral therapy, and with absent-negligible immunodeficiency
Manfredi, R; Sabbatani, S; Calza, L
Brazilian Journal of Infectious Diseases, 11(6): 605-609.

Journal of Infectious Diseases
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
Emery, S; Neuhaus, JA; Phillips, AN; Babiker, A; Cohen, CJ; Gatell, JM; Girard, PM; Grund, B; Law, M; Losso, MH; Palfreeman, A; Wood, R
Journal of Infectious Diseases, 197(8): 1133-1144.
Plos One
Sampling-Based Approaches to Improve Estimation of Mortality among Patient Dropouts: Experience from a Large PEPFAR-Funded Program in Western Kenya
Yiannoutsos, CT; An, MW; Frangakis, CE; Musick, BS; Braitstein, P; Wools-Kaloustian, K; Ochieng, D; Martin, JN; Bacon, MC; Ochieng, V; Kimaiyo, S
Plos One, 3(): -.
ARTN e3843
American Journal of Epidemiology
The Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN Study)
Vellozzi, C; Brooks, JT; Bush, TJ; Conley, LJ; Henry, K; Carpenter, CCJ; Overton, ET; Hammer, J; Wood, K; Holmberg, SD
American Journal of Epidemiology, 169(5): 642-652.
AIDS Patient Care and Stds
Prevalence and Correlates of Elevated Body Mass Index among HIV-Positive and HIV-Negative Women in the Women's Interagency HIV Study
Boodram, B; Plankey, MW; Cox, C; Tien, PC; Cohen, MH; Anastos, K; Karim, R; Hyman, C; Hershow, RC
AIDS Patient Care and Stds, 23(): 1009-1016.
Journal of Infectious Diseases
High-Density Lipoprotein Particles and Markers of Inflammation and Thrombotic Activity in Patients with Untreated HIV Infection
Baker, J; Ayenew, W; Quick, H; Hullsiek, KH; Tracy, R; Henry, K; Duprez, D; Neaton, JD
Journal of Infectious Diseases, 201(2): 285-292.
Journal of Clinical Epidemiology
A comparison of ad hoc methods to account for non-cancer AIDS and deaths as competing risks when estimating the effect of HAART on incident cancer AIDS among HIV-infected men
Shiels, MS; Cole, SR; Chmiel, JS; Margolick, J; Martinson, J; Zhang, ZF; Jacobson, LP
Journal of Clinical Epidemiology, 63(4): 459-467.
Enfermedades Infecciosas Y Microbiologia Clinica
Epidemiological and clinical usefulness of HIV/AIDS cohort studies: Towards a global collaboration
Chene, G
Enfermedades Infecciosas Y Microbiologia Clinica, 25(1): 3-4.

Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count
Phillips, AN; Gazzard, B; Gilson, R; Easterbrook, P; Johnson, M; Walsh, J; Leen, C; Fisher, M; Orkin, C; Anderson, J; Pillay, D; Delpech, V; Sabin, C; Schwenk, A; Dunn, D; Gompels, M; Hill, T; Porter, K; Babiker, A
AIDS, 21(): 1717-1721.

AIDS Patient Care and Stds
Predictors of AIDS-Related morbidity and mortality in a southern US cohort
Mugavero, MJ; Pence, BW; Whetten, K; Leserman, J; Swartz, M; Stangl, D; Thielman, NM
AIDS Patient Care and Stds, 21(9): 681-690.
International Journal of Std & AIDS
How does HIV impact on non-AIDS events in the era of HAART?
Barber, TJ; Hughes, A; Dinsmore, WW; Phillips, A
International Journal of Std & AIDS, 20(1): 1-3.
Annals of Internal Medicine
Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City
Sackoff, JE; Hanna, DB; Pfeiffer, MR; Torian, LV
Annals of Internal Medicine, 145(6): 397-406.

Journal of Infectious Diseases
Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults
Dunn, D; Woodburn, P; Duong, T; Peto, J; Phillips, A; Gibb, D; Porter, K
Journal of Infectious Diseases, 197(3): 398-404.
American Journal of Epidemiology
Gender differences in HIV progression to AIDS and death in industrialized countries: Slower disease progression following HIV seroconversion in women
Jarrin, I; Geskus, R; Bhaskaran, K; Prins, M; Perez-Hoyos, S; Muga, R; Hernandez-Aguado, I; Meyer, L; Porter, K; del Amo, J
American Journal of Epidemiology, 168(5): 532-540.
Canadian Family Physician
Time to deliver on HIV care - Lessons from AIDS 2006 for Canadian family physicians
Kendall, CE; Guenter, D
Canadian Family Physician, 52(): 1449-1450.

International Journal of Clinical Practice
Why do patients fail HIV therapy?
Waters, L; Nelson, M
International Journal of Clinical Practice, 61(6): 983-990.
Journal of Neurosurgery
Introduction - Neurological manifestations of acquired immunodeficiency syndrome
Markowitz, NP; Rosenblum, ML
Journal of Neurosurgery, 107(6): 1251-1252.
HIV Medicine
British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010
Brook, G; Main, J; Nelson, M; Bhagani, S; Wilkins, E; Leen, C; Fisher, M; Gilleece, Y; Gilson, R; Freedman, A; Kulasegaram, R; Agarwal, K; Sabin, C; Deacon, C
HIV Medicine, 11(1): 1-30.
Epidemiologia & Prevenzione
AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era
Zucchetto, A; Bruzzone, S; De Paoli, A; Regine, V; Pappagallo, M; Dal Maso, L; Serraino, D; Rezza, G; Suligoi, B
Epidemiologia & Prevenzione, 33(): 184-189.

American Journal of Epidemiology
Cause-Specific Life Expectancies After 35 Years of Age for Human Immunodeficiency Syndrome-Infected and Human Immunodeficiency Syndrome-Negative Individuals Followed Simultaneously in Long-term Cohort Studies, 1984-2008
Wada, N; Jacobson, LP; Cohen, M; French, A; Phair, J; Munoz, A
American Journal of Epidemiology, 177(2): 116-125.
International Journal of Infectious Diseases
Older HIV-infected patients-an underestimated population in northern Greece: epidemiology, risk of disease progression and death
Metallidis, S; Tsachouridou, O; Skoura, L; Zebekakis, P; Chrysanthidis, T; Pilalas, D; Bakaimi, I; Kollaras, P; Germanidis, G; Tsiara, A; Galanos, A; Malisiovas, N; Nikolaidis, P
International Journal of Infectious Diseases, 17(): E883-E891.
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy
Lima, VD; Hogg, RS; Harrigan, PR; Moore, D; Yip, B; Wood, E; Montaner, JS
AIDS, 21(6): 685-692.
PDF (182) | CrossRef
The role of HIV in serious diseases other than AIDS
Phillips, AN; Neaton, J; Lundgren, JD
AIDS, 22(18): 2409-2418.
PDF (248) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic)
Lewden, C; May, T; Rosenthal, E; Burty, C; Bonnet, F; Costagliola, D; Jougla, E; Semaille, C; Morlat, P; Salmon, D; Cacoub, P; Chêne, G; on behalf of the ANRS EN19 Mortalité Study Group and Mortavic1,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 48(5): 590-598.
PDF (502) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
HIV Diagnosis at CD4 Count Above 500 Cells/mm3 and Progression to Below 350 Cells/mm3 Without Antiretroviral Therapy
The UK Collaborative HIV Cohort (CHIC) Study Steering Committee,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 46(3): 275-278.
PDF (181) | CrossRef
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
Baker, JV; Peng, G; Rapkin, J; Abrams, DI; Silverberg, MJ; MacArthur, RD; Cavert, WP; Henry, WK; Neaton, JD; for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA),
AIDS, 22(7): 841-848.
PDF (193) | CrossRef
AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study
Buchacz, K; Baker, RK; Palella, FJ; Chmiel, JS; Lichtenstein, KA; Novak, RM; Wood, KC; Brooks, JT; and the HOPS Investigators,
AIDS, 24(10): 1549-1559.
PDF (269) | CrossRef
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy
Marin, B; Thiébaut, R; Bucher, HC; Rondeau, V; Costagliola, D; Dorrucci, M; Hamouda, O; Prins, M; Walker, S; Porter, K; Sabin, C; Chêne, G
AIDS, 23(13): 1743-1753.
PDF (343) | CrossRef
AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment
on behalf of the Australian HIV Observational Database, the TREAT Asia HIV Observational Database, ; Falster, K; Choi, JY; Donovan, B; Duncombe, C; Mulhall, B; Sowden, D; Zhou, J; Law, MG
AIDS, 23(17): 2323-2336.
PDF (11481) | CrossRef
The American Journal of the Medical Sciences
Causes of Death in the Era of Highly Active Antiretroviral Therapy: A Retrospective Analysis of a Hybrid Hematology-Oncology and HIV Practice and the Seattle/King County Adult/Adolescent Spectrum of HIV-Related Diseases Project
The American Journal of the Medical Sciences, 336(3): 217-223.
PDF (160) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm3
Lau, B; Gange, SJ; Moore, RD
JAIDS Journal of Acquired Immune Deficiency Syndromes, 44(2): 179-187.
PDF (275) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Risk of Hepatitis-Related Mortality Increased Among Hepatitis C Virus/HIV-Coinfected Drug Users Compared With Drug Users Infected Only With Hepatitis C Virus: A 20-Year Prospective Study
Smit, C; van den Berg, C; Geskus, R; Berkhout, B; Coutinho, R; Prins, M
JAIDS Journal of Acquired Immune Deficiency Syndromes, 47(2): 221-225.
PDF (134) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Trends in Mortality and Causes of Death Among Women With HIV in the United States: A 10-Year Study
French, AL; Gawel, SH; Hershow, R; Benning, L; Hessol, NA; Levine, AM; Anastos, K; Augenbraun, M; Cohen, MH
JAIDS Journal of Acquired Immune Deficiency Syndromes, 51(4): 399-406.
PDF (340) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases
Baker, JV; Peng, G; Rapkin, J; Krason, D; Reilly, C; Cavert, WP; Abrams, DI; MacArthur, RD; Henry, K; Neaton, JD; for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA),
JAIDS Journal of Acquired Immune Deficiency Syndromes, 48(5): 541-546.
PDF (936) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Temporal Changes in Causes of Death Among HIV-Infected Patients in the HAART Era in Rio de Janeiro, Brazil
Pacheco, AG; Tuboi, SH; May, SB; Moreira, LF; Ramadas, L; Nunes, EP; Merçon, M; Faulhaber, JC; Harrison, LH; Schechter, M
JAIDS Journal of Acquired Immune Deficiency Syndromes, 51(5): 624-630.
PDF (129) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Untreated HIV Infection and Large and Small Artery Elasticity
Baker, JV; Duprez, D; Rapkin, J; Hullsiek, KH; Quick, H; Grimm, R; Neaton, JD; Henry, K
JAIDS Journal of Acquired Immune Deficiency Syndromes, 52(1): 25-31.
PDF (187) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Survival After AIDS Diagnosis in Italy, 1999-2006: A Population-Based Study
Serraino, D; Zucchetto, A; Suligoi, B; Bruzzone, S; Camoni, L; Boros, S; Paoli, AD; Maso, LD; Franceschi, S; Rezza, G
JAIDS Journal of Acquired Immune Deficiency Syndromes, 52(1): 99-105.
PDF (345) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Response to “Censoring Strategies When Using Competing Risks With Time-Dependent Covariates”
del Amo, J; Pérez-Hoyos, S
JAIDS Journal of Acquired Immune Deficiency Syndromes, 46(4): 512-513.
PDF (277) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients
Antiretroviral Therapy Cohort Collaboration,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 46(5): 607-615.
PDF (268) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Differential Survival Benefit of Universal HAART Access in Brazil: A Nation-Wide Comparison of Injecting Drug Users Versus Men Who Have Sex With Men
Malta, M; Bastos, FI; da Silva, CM; Pereira, GF; Lucena, FF; Fonseca, MG; Strathdee, SA
JAIDS Journal of Acquired Immune Deficiency Syndromes, 52(5): 629-635.
PDF (172) | CrossRef
Journal of Hypertension
Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy
Baekken, M; Os, I; Sandvik, L; Oektedalen, O
Journal of Hypertension, 26(11): 2126-2133.
PDF (162) | CrossRef
Back to Top | Article Outline

HIV; cohort; seroconverters; causes of death; highly active antiretroviral therapy

© 2006 Lippincott Williams & Wilkins, Inc.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.